Saturday 17 October 2026 Export SYBX’s income statement to Excel — free account

Synlogic, Inc.

Synlogic, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8,000.00, down 99.8% from fiscal 2023. In the quarter to June 2026, EPS was flat and free cash flow fell 277.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.00 0.08 −7.41%

Follow SYBX

Alert me

Market cap: $6.7M
P/E: 0.0×
Fwd P/E: −2.8×
Dividend yield: —
F-score: 3/9
Altman Z: −35.79
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 42.83%

Capital & Financial Ratios $m

Market Cap 6.68

Revenue 3.21

Net Income (0.65)

Free Cash Flow (3.84)

Net Debt (13.18)

Current Ratio 9.19

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (2.80)

P/S ratio 3.87

P/B ratio 1.03

Past 5Y EPS Growth —

This Y EPS Growth 85.81%

Next Y EPS Growth 82.66%

Next Y revenue growth 55,875.00%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 7.19%

10-year low 10-year high

P/B against its own 10 years 57.32%

10-year low 10-year high

EV/FCF against its own 10 years 22.73%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	48	19	15	13
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	0	—	—
	50	20	15	13

	2023	2024	2025	Q'26
Payables	1	0	0	0
ST’ Debt	—	—	—	—
Other	—	—	—	—
	30	7	4	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	(67.55%)	(83.42%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(17.88%)	(36.53%)	(47.63%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	0	—	—	—	0
’23	0	0	0	3	3
’22	0	0	1	0	1
’21	—	0	1	1	2
’20	0	0	—	0	1
’19	0	0	0	1	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(2)	0	(1)	(1)	(4)
’24	(15)	(15)	(1)	(1)	(32)
’23	(22)	(12)	(13)	(6)	(52)
’22	(15)	(14)	(15)	(12)	(57)
’21	(14)	(11)	(14)	(13)	(52)
’20	(12)	(9)	(8)	(10)	(40)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(2)	0	(1)	(1)	(4)
’24	(16)	(14)	(1)	(1)	(30)
’23	(22)	(12)	(13)	(6)	(52)
’22	(16)	(14)	(16)	(12)	(58)
’21	(14)	(11)	(14)	(13)	(53)
’20	(13)	(9)	(8)	(10)	(40)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.05	(0.04)	—	—	—
’25	0.03	(0.04)	(0.19)	0.12	(0.08)
’24	(2.60)	0.25	(0.01)	(0.06)	(1.92)
’23	(3.45)	(3.15)	(2.57)	(1.71)	(8.81)
’22	(3.30)	(3.30)	(3.75)	(3.60)	(13.79)
’21	(5.40)	(4.20)	(4.35)	(3.15)	(16.34)
’20	(6.90)	(6.60)	(5.40)	(5.85)	(24.74)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	117.60	131.40	86.25	28.65	20.25	32.25	8.25	1.61	1.22	0.90	Analyst estimates 2026–2028 Powerpack
	High	698.25	345.00	225.00	171.41	59.85	76.65	39.75	16.50	5.12	1.96
People
People	Employees	9	63	74	76	72	84	72	6	1	1
	Revenue/emp, $m	0.05	0.04	0.03	0.03	0.01	0.02	0.02	0.56	0.01	0.00
Income, $m
Income, $m	Revenue	0	2	3	2	1	2	1	3	0	—
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	—
	EBT	(21)	(40)	(48)	(51)	(59)	(61)	(66)	(61)	(23)	(1)
	EBT margin, %	(4,719.37)	(1,652.09)	(1,922.02)	(2,309.94)	(10,857.43)	(3,452.74)	(5,605.68)	(1,817.24)	(291,925.00)	0.00
	Net income	(21)	(40)	(48)	(51)	(59)	(61)	(66)	(61)	(23)	(1)
	Depreciation	1	2	1	1	3	3	2	1	0	—
Per share, $
Per share, $	Revenue	4.22	5.45	1.58	1.10	0.23	0.48	0.25	0.52	0.00	0.00
	Earnings	(199.34)	(89.95)	(30.43)	(25.49)	(24.74)	(16.34)	(13.79)	(8.81)	(1.92)	(0.08)
	Cash flow	(194.18)	(69.23)	(26.66)	(37.36)	(16.55)	(14.14)	(11.90)	(7.94)	(2.60)	(0.35)
	Capex	(17.44)	(5.72)	(3.55)	(0.62)	(0.17)	(0.18)	(0.15)	(0.03)	0.11	0.01
	Free cash flow	(211.62)	(74.95)	(30.21)	(37.98)	(16.71)	(14.33)	(12.05)	(7.97)	(2.49)	(0.34)
	Book value	128.48	189.56	77.90	77.68	48.17	39.90	17.28	5.04	1.05	0.96
	Shares, m	0	0	2	2	2	4	5	7	12	12
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
	P/S	0.00	29.74	66.47	35.15	43.61	76.38	45.10	8.62	5.33	—
	P/B	0.00	0.85	1.35	0.50	0.67	0.91	0.64	0.89	1.34	—
	EV/Sales	0.00	(5.68)	17.85	(18.61)	(1.53)	3.08	(20.68)	(5.54)	(0.56)	—
	EV/FCF	(0.25)	0.41	(0.93)	0.54	0.07	(0.10)	0.42	0.36	0.06	—
Cash, $m
Cash, $m	Operating cash flow	(20)	(31)	(42)	(75)	(40)	(52)	(57)	(52)	(32)	(4)
	Capex	(2)	(3)	(6)	(1)	0	(1)	(1)	0	1	0
	Free cash flow	(22)	(34)	(48)	(77)	(40)	(53)	(58)	(52)	(30)	(4)
Balance, $m
Balance, $m	Working capital	12	80	116	124	99	123	68	20	13	12
	Total debt	0	0	0	0	20	0	0	—	—	—
	Net debt	(14)	(87)	(123)	(120)	(80)	(129)	(78)	(48)	(19)	(15)
	Shareholders’ equity	14	85	124	157	115	147	83	33	13	12
Returns, %
Returns, %	ROA	(37.77)	(67.44)	(40.36)	(31.24)	(35.60)	(38.02)	(46.32)	(65.74)	(48.98)	(5.70)
	ROIC	0.00	0.00	(2,027.79)	(91.08)	(108.09)	(203.14)	(845.27)	0.00	0.00	0.00
	ROE	(77.09)	(148.49)	(46.32)	(36.56)	(43.50)	(46.16)	(57.55)	(106.21)	(102.63)	(8.17)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Mar 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SKYE Skye Bioscience, Inc.	$7.0M	— (loss-making)	—	−34.71% (below 0%: shrinking)	n/m	+34.84% (above 0%: growing)	72.71%	0.00%	Compare
BCLI Brainstorm Cell Therapeutics Inc.	$7.0M	— (loss-making)	—	—	n/m	+74.44% (above 0%: growing)	0.00%	0.00%	Compare
CLGN CollPlant Biotechnologies Ltd. Sponsored ADR	$7.0M	— (loss-making)	— (loss-making)	−39.66% (below 0%: shrinking)	n/m	+5.08% (above 0%: growing)	(422.22%)	(2,437.96%)	Compare
NIKI Niki BioSolutions, Inc.	$6.9M	— (loss-making)	31.9×	−32.36% (below 0%: shrinking)	+69.51% (above 0%: growing)	+58.14% (above 0%: growing)	(154.22%)	0.00%	Compare
AIM AIM ImmunoTech Inc.	$6.8M	— (loss-making)	— (loss-making)	+4.00% (above 0%: growing)	n/m	−167.46% (below 0%: shrinking)	80.77%	(13,511.54%)	Compare
SYBX Synlogic, Inc.	$6.7M	— (loss-making)	— (loss-making)	−95.40% (below 0%: shrinking)	n/m	−277.87% (below 0%: shrinking)	100.00%	0.00%
FBLG FibroBiologics Inc.	$6.7M	— (loss-making)	—	—	n/m	+21.59% (above 0%: growing)	—	0.00%	Compare
ACXP Acurx Pharmaceuticals, Inc.	$6.5M	— (loss-making)	—	—	n/m	−2.36% (below 0%: shrinking)	—	0.00%	Compare
TCRT Alaunos Therapeutics, Inc.	$6.4M	— (loss-making)	— (loss-making)	+200.00% (above 0%: growing)	n/m	+57.20% (above 0%: growing)	100.00%	0.00%	Compare
Median of peers	$6.9M	—	—	−32.36%	—	+28.22%	36.36%	0.00%

All 614 Biotechnology stocks →

Synlogic, Inc. (SYBX) key facts

Concern: Synlogic, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8,000.00, down 99.8% from fiscal 2023.
Synlogic, Inc. (SYBX) is a Biotechnology company in the Healthcare sector.
As of October 16, 2026, SYBX traded at $1.00, a market capitalization of $6.7 million.
Return on equity was −8.17% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −35.79 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.